Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Washington

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medical treatments and their potential long-term consequences. This legacy framework emphasizes the importance of informed consent, patient monitoring, and the recognition that therapeutic interventions carry inherent risks. Within this broad context, the transition from general health awareness to specific occupational exposure concerns requires a focused lens on how certain medications, initially developed for chronic conditions, may present unique hazards in particular environments. In the domain of mass production, where biological materials and pharmaceutical agents are handled at scale, the risk landscape shifts from patient-centered considerations to worker safety protocols. The medication Tysabri, used in the treatment of multiple sclerosis and Crohn’s disease, has been associated with a rare but serious condition known as progressive multifocal leukoencephalopathy (PML). For individuals in manufacturing or laboratory settings who may have been exposed to this drug—whether through direct handling, accidental contamination, or environmental residues—the concern moves beyond clinical efficacy to occupational hazard assessment. This pivot from general health literacy to workplace exposure underscores the need for vigilance in industrial hygiene practices. It also raises questions about legal recourse for those affected, particularly regarding the statute of limitations for filing claims in jurisdictions such as Washington.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the central nervous system, leading to demyelination and progressive neurological decline. Clinical presentation of PML typically includes subacute onset of focal neurological deficits such as hemiparesis, visual field cuts, ataxia, cognitive impairment, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The condition is often fatal or results in permanent severe disability, as noted in the boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 beta-1 integrin on leukocytes, blocking their adhesion to vascular cell adhesion molecule-1 on endothelial cells. This prevents immune cells from crossing the blood-brain barrier, reducing central nervous system inflammation in multiple sclerosis. However, this immunosuppressive effect also impairs normal immune surveillance against JCV in the brain, allowing the virus to replicate unchecked and cause PML. The risk is stratified by three factors: presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are JCV antibody-positive, have received more than two years of Tysabri treatment, or have previously used immunosuppressive medications face the highest risk. Adverse event data from the FDA Adverse Event Reporting System (FAERS) show that Tysabri is associated with a wide range of neurological and systemic complaints. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they underscore the drug's significant neurological side-effect profile.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a critical issue. The prescribing information includes a boxed warning that clearly states the increased risk of PML and the need for monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in the TOUCH Prescribing Program, which requires them to read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers were adequately informed about the magnitude of risk, especially in the context of long-term therapy. The boxed warning emphasizes that risk factors should be considered when initiating and continuing treatment, but the balance of benefit versus risk may not always be clearly communicated to patients. For affected patients in Washington, attorney-related considerations involve the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, the timeline between exposure and documented harm is variable. PML can develop after months to years of treatment, as noted in the prescribing information for herpes infections, where onset ranged from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the determination of when the injury was discovered. Patients who develop PML may experience progressive neurological decline, and the diagnosis may be delayed due to symptom overlap with multiple sclerosis. Legal counsel should be sought promptly to assess individual circumstances and ensure compliance with Washington's filing deadlines.

Conclusion and Next Steps

In summary, Tysabri carries a well-documented risk of PML, a severe and often fatal brain infection. The drug's mechanism of action—blocking immune cell entry into the brain—creates a vulnerability to JCV reactivation. While the prescribing information includes warnings and a restricted distribution program, the adequacy of these warnings may be contested in legal contexts. For Washington patients, the statute of limitations requires timely action after discovery of harm, given the variable latency between Tysabri exposure and PML onset. If you or a loved one has been affected, it is important to consult with an attorney experienced in pharmaceutical litigation to understand your rights and the applicable deadlines.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML associated with Tysabri, the latency period can complicate this timeline, so prompt legal consultation is advised.

What are the risk factors for developing PML while on Tysabri?

The risk of PML is stratified by three factors: presence of anti-JCV antibodies, duration of therapy (especially over two years), and prior use of immunosuppressants. Patients with these risk factors face the highest risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the early symptoms of PML?

Early symptoms of PML include subacute onset of focal neurological deficits such as hemiparesis, visual field cuts, ataxia, cognitive impairment, and speech difficulties. These symptoms can overlap with multiple sclerosis, making early diagnosis challenging.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.